Sirtex Medical (ASX:SRX) saw shares tumble more than 25% today after a trial of its radioactive microspheres reported no effect in improving survival in patients with colorectal cancer.
Results from the Foxfire analysis study indicated that the use of SIR-Spheres Y-90 microspheres in combination with chemotherapy did not improve overall survival in patients with unresectable colorectal cancer compared to chemotherapy alone, the Woburn, Mass.-based company said.
Read the whole story at our sister site, Drug Delivery Business
The post Sirtex SIR-Spheres fail to improve survival in colorectal trial appeared first on MassDevice.
from MassDevice http://ift.tt/2rwMYNE
Cap comentari:
Publica un comentari a l'entrada